🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the infection, according to researchers.

An International Challenge

The sexually transmitted infection are on the rise around the world, with estimates suggesting over 82 million instances each year. Particularly high rates are seen in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the treatment of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per findings released by a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which combines two antibiotics. The trial included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Clinicians directly involved have shared positive views. Access to a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is viewed as vital to reduce the burden of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.